<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR84">
 <label>84.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rizvi</surname>
    <given-names>NA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial</article-title>
  <source>Lancet Oncol</source>
  <year>2015</year>
  <volume>16</volume>
  <issue>3</issue>
  <fpage>257</fpage>
  <lpage>265</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(15)70054-9</pub-id>
  <?supplied-pmid 25704439?>
  <pub-id pub-id-type="pmid">25704439</pub-id>
 </element-citation>
</ref>
